Banner for leaf pages 2

Dasatinib

Also known as Sprycel

Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.

Source: Wikipedia

Estimated Total Cost: $5715.17 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed dasatinib to treat rabies, blastomycosis, west nile virus, and pick disease.

Ajax-loader Loading...